Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients

MLA

Catherine Roche-Lestienne, et al. “Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.” Blood, vol. 110, Nov. 2007, p. 2847. EBSCOhost, https://doi.org/10.1182/blood.v110.11.2847.2847.

APA

Catherine Roche-Lestienne, Aline Renneville, Florence Pasquier, Pierre Fenaux, Selim Corm, Claude Preudhomme, Charikleia Kelaidi, Sylvie Castaigne, Virginie Eclache, Gérard Michel, & Nathalie Philippe. (2007). Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients. Blood, 110, 2847. https://doi.org/10.1182/blood.v110.11.2847.2847

Chicago

Catherine Roche-Lestienne, Aline Renneville, Florence Pasquier, Pierre Fenaux, Selim Corm, Claude Preudhomme, Charikleia Kelaidi, et al. 2007. “Evaluation of Minimal Residual Disease Based on NPM1 Mutations in AML with Intermediate Risk Cytogenetics: A Prospective Study of 36 Patients.” Blood 110 (November): 2847. doi:10.1182/blood.v110.11.2847.2847.